GET DAILY SIGNALSADC Therapeutics (ADCT): Analyst Consensus Points to $4.00 Target and a Potential +153% Move
Key Takeaways
- The $4.00 central target is the arithmetic mean of the three most current, individually verified analyst price targets — $2.00 (RBC Capital), $5.00 (Guggenheim) and $5.00 (Stephens) — across a range of $2.00 to $5.00.
- At roughly $1.58 per share, reaching $4.00 would require a gain of about 153%, a very large move by any standard.
- Analyst targets have fallen sharply from $8–$10 levels after the LOTIS-5 safety setback, yet the remaining Buy-rated targets of $5 each still sit far above the current price.
- The strongest supports are a $219 million cash position, a cash runway into at least 2028, and full LOTIS-7 data expected in late 2026.
- The biggest risk is the FDA's "substantial concerns" about LOTIS-5's benefit-risk profile after elevated Grade 5 (fatal) adverse events.
- For more context, explore Major News, Today's Price Move, the Forecast, and Earnings pages for this ticker.
- You can also explore Trending AI Robots for AI-driven trading ideas across thousands of stocks and ETFs.
Analyst Price Targets and Consensus View
ADC Therapeutics SA (ADCT), a Swiss commercial-stage biotechnology company pioneering antibody-drug conjugates (ADCs), is covered by a small but divided group of analysts. The three most current, individually attributed targets produce a mean of $4.00: RBC Capital's Leonid Timashev holds a $2.00 target with a Hold rating (maintained in October 2026 after a June downgrade from Outperform), while Guggenheim's Michael Schmidt reiterated Buy at $5.00 in August 2026 (down from $10) and Stephens reiterated Buy at $5.00 in June 2026 (down from $8). HC Wainwright, which previously carried an $8 target, downgraded the stock to Neutral in June 2026 and dropped its target.
The $2.00-to-$5.00 spread is wide and reflects genuine disagreement: cautious voices argue the safety overhang caps the stock, while bullish analysts see the valuation and pipeline as undervaluing an approved, revenue-generating product. Some data aggregators citing up to five analysts report a slightly lower average near $3.33, underscoring that the aggregate is an arithmetic calculation, not a guarantee or an official published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Current Market Position and Path Toward the Target
ADCT trades near $1.58, with a 52-week range of roughly $0.78 to $4.98. Reaching the $4.00 central target would therefore require an advance of about 153% — a very large move that would return the shares near their recent 52-week high.
The stock crashed about 66% in the weeks after the June 2026 topline readout of the Phase 3 LOTIS-5 trial, which met its primary endpoint of progression-free survival but showed elevated Grade 5 treatment-emergent adverse events (13.2% versus 4.6% for control) and no overall-survival benefit. Since that reset, the shares have partially recovered. The path to $4.00 would likely require resolving the regulatory uncertainty, delivering favorable LOTIS-7 data, and rebuilding commercial momentum for ZYNLONTA (loncastuximab tesirine-lpyl), the company's CD19-directed ADC approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
What Could Support a Move Toward the Target
Several factors could underpin a recovery. The company held $219.1 million in cash as of June 30, 2026, with a runway extending into at least 2028, reducing near-term dilution risk. A 17% workforce reduction should yield roughly $10 million in annual savings. LOTIS-7, evaluating ZYNLONTA with glofitamab, enrolled 100 patients at the selected dose with full data expected in the fourth quarter of 2026; a favorable readout could reframe the benefit-risk debate. ZYNLONTA's existing accelerated-approval monotherapy indication also continues to generate revenue — $18.6 million in Q2 2026 — providing a commercial foundation most development-stage peers lack.
What Could Prevent the Target From Being Reached
The principal obstacle is regulatory. At an August 2026 pre-submission meeting, the FDA expressed "substantial concerns" about LOTIS-5's benefit-risk profile and verification of the treatment benefit, prompting the company to reassess the path toward an sBLA (supplemental Biologics License Application). The elevated fatal-adverse-event signal, largely infection-driven and concentrated in patients aged 75 and older, could delay or narrow any label expansion into earlier lines of DLBCL. Persistent losses, modest revenue growth, and execution risk around LOTIS-7 all represent additional hurdles.
Technical Levels and Market Structure
The shares sit well above the 52-week low near $0.78, where buyers stepped in after the post-LOTIS-5 selloff, and well below the $4.98 high. The $2.00 level — the low end of the analyst range and a psychological round number — marks the first meaningful resistance, while $4.00 and $5.00 represent progressively higher zones. A sustained move above $2.00 would likely be needed to shift the longer-term trend structure from recovery to genuine re-rating.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a roughly 12-month research horizon, though firms do not always state one explicitly and timelines vary. Investors should watch the full LOTIS-7 data (expected Q4 2026), any updated regulatory strategy for LOTIS-5 and a possible sBLA submission, the American Society of Hematology presentations, quarterly ZYNLONTA revenue trends, and cash-burn trajectory. Further analyst revisions — which have trended downward this year — would also signal shifting sentiment. From what I see, monitoring these catalysts closely remains essential.
Leveraging Tickeron’s AI Daily Buy/Sell Signals
I have found Tickeron’s AI Daily Buy/Sell Signals useful for tracking names like ADCT. The system applies artificial intelligence to scan thousands of stocks and ETFs in real time, producing Buy, Sell, or Hold signals whenever market conditions or technical patterns shift. For a volatile biotech holding, these signals can help surface momentum changes ahead of broader market recognition and complement manual review of clinical and regulatory updates.
Final Assessment
The $4.00 central target reflects the average of three current, verifiable analyst targets across a wide $2.00-to-$5.00 range, and represents a very large 153% move from the current price near $1.58. The bull case rests on cash runway, an approved product, and a potentially favorable LOTIS-7 readout, while the bear case centers on the FDA's LOTIS-5 safety concerns and the risk of a delayed or narrowed label expansion. With such a wide spread of targets and a binary clinical catalyst ahead, the outcome depends heavily on regulatory and data events rather than valuation alone. Investors should monitor LOTIS-7 data, the regulatory path, and analyst revisions rather than treat the mean target as a forecast.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Aroon Indicator for ADCT shows an upward move is likely
ADCT's Aroon Indicator triggered a bullish signal on October 21, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 151 similar instances where the Aroon Indicator showed a similar pattern. In 134 of the 151 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 58 of 67 cases where ADCT's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
Following a +11.69% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADCT advanced for three days, in 183 of 226 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Bearish Trend Analysis
The 10-day RSI Indicator for ADCT moved out of overbought territory on October 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 21 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ADCT as a result. In 86 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for ADCT turned negative on November 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 48 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADCT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ADCT broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.884) is normal, around the industry mean (6.379). P/E Ratio (-2.724) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.062) among similar stocks. P/S Ratio (1.967) is also within normal values, averaging (183.387).
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. ADCT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 77 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADCT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry PharmaceuticalsGeneric